Invasive candidiasis

Active Ingredient: Rezafungin

Indication for Rezafungin

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Rezafungin is indicated for the treatment of invasive candidiasis in adults.

Consideration should be given to official guidance on the appropriate use of antifungal agents.

For this indication, competent medicine agencies globally authorize below treatments:

400 mg on Day 1, 200 mg on Day 8 and thereafter 200 mg once weekly

For:

Dosage regimens

Intravenous, 400 milligrams rezafungin, one dose, over the duration of 7 days. Afterwards, intravenous, 200 milligrams rezafungin, once weekly.

Detailed description

A single 400 mg loading dose on Day 1, followed by 200 mg on Day 8 and once weekly thereafter.

The duration of treatment should be based upon the patient’s clinical and microbiological response. In general, antifungal therapy should continue for at least 14 days after the last positive culture. During clinical trials patients were treated with rezafungin for up to 28 days. The safety information on rezafungin treatment durations longer than 4 weeks is limited.

If a scheduled dose is missed (not given on the assigned day) the missed dose should be administered as soon as possible.

  • If the missed dose is administered within 3 days of the assigned day, the next weekly dose may be given on schedule.
  • If the missed dose is administered more than 3 days after the assigned day, the dosing schedule should be revised to ensure there are at least 4 days before the next dose.
  • If administration is restarted after at least 2 weeks of missed dosing, the dosing should be started again at the 400 mg loading dose.

Dosage considerations

After reconstitution and dilution, the solution should be administered by slow intravenous infusion over approximately 1 hour, infusion time may be increased up to 180 minutes to manage any evolving symptoms of infusion-related reaction.

Active ingredient

Rezafungin

Rezafungin selectively inhibits fungal 1,3-β-D-glucan synthase. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall which is not present in mammalian cells. Inhibition of 1,3-β-D-glucan synthesis results in rapid and concentration-dependent fungicidal activity in Candida species (spp.).

Read more about Rezafungin

Related medicines

Structured Product Labeling (SPL/PLR) 2023: REZZAYO Powder for solution for injection
Summary of Product Characteristics (SPC) 2024: REZZAYO Powder for solution for infusion

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.

⇈